First Time Loading...

Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 20.13 USD 2.86% Market Closed
Updated: May 2, 2024

Veracyte Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Veracyte Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Veracyte Inc
NASDAQ:VCYT
Revenue
$361.1m
CAGR 3-Years
45%
CAGR 5-Years
31%
CAGR 10-Years
32%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Veracyte Inc
Revenue Breakdown

Breakdown by Geography
Veracyte Inc

Total Revenue: 361.1m USD
100%
United States: 334.5m USD
92.7%
International: 26.5m USD
7.3%

Breakdown by Segments
Veracyte Inc

Total Revenue: 361.1m USD
100%
Testing Revenue: 326.5m USD
90.4%
Biopharmaceutical And Other Revenue: 18.9m USD
5.2%
Product Revenue: 15.6m USD
4.3%
Other Testing Revenue: 7.8m USD
2.2%
Show More
Show Less

See Also

What is Veracyte Inc's Revenue?
Revenue
361.1m USD

Based on the financial report for Dec 31, 2023, Veracyte Inc's Revenue amounts to 361.1m USD.

What is Veracyte Inc's Revenue growth rate?
Revenue CAGR 10Y
32%

Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Veracyte Inc have been 45% over the past three years , 31% over the past five years , and 32% over the past ten years .